Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 1Phase 1/2 1

Status

Completed 4

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 25Hodgkin Disease 20Lymphoma 9Skin Neoplasms 4Neoplasm Metastasis 4Sarcoma 3Leiomyosarcoma 3Neuroblastoma 2Neoplasms 2Uveal Melanoma 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Melanoma, Cutaneous Malignant 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Liposarcoma 1

Interventions

Dacarbazine 4pembrolizumab 3binimetinib 3Nivolumab 3encorafenib 2cemiplimab 2Sirolimus 2Ipilimumab 2vitespin 1trametinib 1tilsotolimod 1spartalizumab 1oblimersen 1linrodostat 1lifileucel 1gp100 Melanoma Antigen 1dabrafenib 1bempegaldesleukin 1aldesleukin 1Vinblastine 1Vemurafenib 1Tretinoin 1Tacrolimus 1Standard of Care 1Sodium Chloride 1Radiotherapy 1Radiation 1Interleukin-2 1Interferon-alpha 1Interferon alpha-2 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 3 × Skin Neoplasms × Dacarbazine × Clear all
NCT01763164 2021-03-22

Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma

Pfizer

Phase 3 Completed
402 enrolled 21 charts
Dermatologic

Melanoma, Neoplasm Metastasis, Skin Diseases, Skin Neoplasms

NCT00002882 2011-12-13

Interferon Alfa With or Without Combination Chemotherapy Plus Interleukin-2 in Treating Patients With Melanoma

M.D. Anderson Cancer Center

Phase 3 Completed
140 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT00518895 2011-11-07

AGENDA

Genta Incorporated

Phase 3 Completed
300 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT00003647 2008-07-25

Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma

Vical

Phase 3 Completed
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡